FRAX597 is a potent and selective inhibitor of p21-activated kinases (PAKs), particularly targeting group I PAKs (PAK1-3). Its primary application lies in preclinical research for oncology, where it is used to study signaling pathways involved in tumor growth, survival, and metastasis. By inhibiting PAK activity, FRAX597 has demonstrated the ability to suppress proliferation in cancer cell lines with hyperactive PAK signaling, including those derived from melanoma, breast cancer, and pancreatic cancer. It is also employed in research on neurofibromatosis type 1 (NF1), where loss of the NF1 tumor suppressor leads to increased PAK activation. FRAX597 has shown efficacy in reducing tumor size in NF1-related preclinical models, making it a valuable tool for evaluating PAK inhibition as a therapeutic strategy. Additionally, FRAX597 is used to investigate the role of PAKs in cytoskeletal dynamics, cell motility, and synaptic function, extending its utility into studies of neurological disorders and cellular morphology. Due to its selectivity and cell permeability, it is favored in pharmacological studies aiming to dissect PAK-dependent pathways and assess the therapeutic potential of PAK inhibition.